Anzeige
Mehr »
Lynx Broker
Login
Donnerstag, 17.10.2019 Börsentäglich über 12.000 News von 614 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 858560 ISIN: US5324571083 Ticker-Symbol: LLY 
Xetra
17.10.19
15:19 Uhr
97,50 Euro
-0,50
-0,51 %
Branche
Pharma
Aktienmarkt
S&P 500
S&P 100
1-Jahres-Chart
ELI LILLY AND COMPANY Chart 1 Jahr
5-Tage-Chart
ELI LILLY AND COMPANY 5-Tage-Chart
RealtimeGeldBriefZeit
97,50
98,00
17:29
97,72
97,93
17:29

Aktuelle News zur ELI LILLY Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
12:31Lilly's pegilodecakin fails in long-shot pancreatic cancer trial-
MiEli Lilly Drug Acquired in Armo Deal Fails Pancreatic Cancer Test-
ELI LILLY Aktien jetzt im kostenlosen Demokonto handeln!
MiEli Lilly's first PhIII showdown for their $1.6B cancer drug just flopped - what now?3
MiEli Lilly Phase 3 Pancreatic Cancer Study Fails to Meet Primary Endpoint2
MiLilly's Armo buyout drug a bust in pancreatic cancer-
MiLilly's pancreatic cancer treatment fails late-stage study-
MiLilly Says Phase 3 SEQUOIA Study Did Not Meet Primary Endpoint185INDIANAPOLIS (dpa-AFX) - Eli Lilly and Co. (LLY) announced Wednesday that top-line results from its Phase 3 SEQUOIA trial evaluating pegilodecakin plus FOLFOX (folinic acid, 5-FU, oxaliplatin)...
► Artikel lesen
MiLilly's pegilodecakin flunks late-stage study; shares down 2% premarket-
MiEli Lilly says late-stage trial of pancreatic cancer treatment failed to meet its main goal of overall survival-
MiEli Lilly shutters UK neuroscience unit, with 80 job losses expected-
DiEli Lilly to shutter neuroscience R&D center next year2
DiLilly Gets FDA Approval for New Oral Tablets for Migraine3
DiThat big neurosciences R&D group Eli Lilly built is being dismantled, with layoffs and parts shipped home-
DiAeglea, long-term Eli Lilly veteran nabs CMO job at Checkmate-
DiLilly to close UK research facility-
DiFDA 'yes' for Eli Lilly's Reyvow-
MoFDA approves Lilly's migraine drug Reyvow1
MoLilly's Taltz successful in late-stage pediatric psoriasis study1
MoEli Lilly gets FDA approval for migraine drug Reyvow1
SaFirst place finish: Eli Lilly just moved to franchise leader with their second migraine drug OK in 1 year3
Seite:  Weiter >>
397 Nachrichten in den letzten 12 Monaten

Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
3,1,6